Flash | 21 Jul 2026 08:39:10 ET │ 10 pages Agios Pharmaceuticals (AGIO.O) Tebapivat Discontinuation Removes an Upside Scenario in Sickle Cell Disease CITI'S TAKE Agios announced discontinuation of tebapivat development in sickle cell disease (SCD) following Ph2 data that did not meet the company's internal bar for further development. While the data demonstrated a hemoglobin response consistent with the PK activator class, the study showed an inconsistent dose response (2.5mg: 43.8%; 5mg: 47.1%; 7.5mg: 29.4 ...